IQVIA Holdings EPS outlook lifted, shares anchored in S&P 500 healthcare tech

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 10:38.

IQVIA Holdings (US46266C1053) has raised its adjusted EPS outlook for 2026 to a range of 12.65 to 12.95 dollars while reaffirming revenue guidance of 17.15 to 17.35 billion dollars, according to recent earnings commentary from specialist outlets that follow the S&P 500-listed healthcare data group.*

What recent analyst notes highlight

Recent sector coverage points to a mixed analyst backdrop around IQVIA Holdings, with one major investment bank lowering its price target to 210 dollars from 240 dollars but keeping a Buy rating on the shares, and another house downgrading the stock from Overweight to Equal Weight while trimming its target to 200 dollars.* Both updates frame IQVIA in the context of broader health-care technology peers such as Veeva Systems and Charles River Laboratories.

The coverage emphasizes IQVIA's role as a large-cap constituent in U.S. healthcare technology, noting its presence in indices such as the S&P 500 and comparing the stock's valuation and earnings trajectory with data-driven peers that serve pharmaceutical and biotech clients.*

Consensus picture for earnings and margins

Consensus expectations, based on recent compiled estimates from market-data platforms, cluster around IQVIA's reaffirmed 2026 revenue corridor of 17.15 to 17.35 billion dollars, with the raised adjusted EPS band of 12.65 to 12.95 dollars signaling moderate margin improvement versus previous guidance.* That places IQVIA alongside other data-heavy healthcare names where margin expansion is driven by software, analytics and contract-research mix.

Analyst summaries underline that IQVIA's guidance implies a steady mid-single-digit to high-single-digit top-line growth profile, with buyback activity in the first quarter - reported at 552 million dollars worth of shares repurchased and a total authorized program of 3.2 billion dollars - supporting per-share earnings dynamics.*

The business behind the stock

IQVIA Holdings generates its revenue by combining contract research services with real-world data and advanced analytics for pharmaceutical, biotech and medical-device clients. A representative offering is its technology-enabled clinical research platform, which integrates trial design, patient recruitment and data management in one stack for global studies.

Where the stock trades today

IQVIA Holdings shares (US46266C1053) trade on the NYSE in U.S. dollars; as of 2026-06-26, 15:59 Eastern, the last regular-session close reported by market-data platforms was around 191 dollars per share, with after-hours indications modestly below that level.*

This article is for informational purposes only and does not contain investment advice, personal recommendations or an offer to buy or sell securities. Figures and dates are based on sources judged reliable at the time of review but may change. Retail investors should consult their own advisers and check updated market data before making decisions.